Altered Cyclic AMP Signaling in Fragile X

With $125,000 grant from FRAXA Research Foundation over 2006-2008, Dr. Anita Bhattacharyya at the University of Wisconsin Waisman Center investigated abnormalities in cyclic AMP signaling in Fragile X syndrome. Results published.

Anita Bhattacharyya
$146,000 Grant
Anita Bhattacharyya, PhD
Principal Investigator
University of Wisconsin
2012-2013 FRAXA Research Grant
$146,000 over 2 Years
Cyclic AMP signaling in Fragile X

This group studies signaling pathways in Fragile X neural stem cells, with a particular interest in abnormalities of cyclic AMP. The use of actual human Fragile X cells allows for an examination of the disorder without the inter-species variability encountered in mouse models.

Cyclic AMP (cAMP) is a second messenger involved in many brain processes including memory processing and anxiety. Memory deficits and anxiety are noted in Fragile X. This team found evidence of altered cAMP cascade function in Fragile X and autism. Cyclic AMP is a potentially useful biochemical marker to distinguish autism with Fragile X from autism per se and the cAMP cascade may also be a viable therapeutic target for both Fragile X and autism.

by Anita Bhattacharyya

Fragile X syndrome is defined by the loss of Fragile X mental retardation protein (FMRP). We are exploring how cellular processes are affected by the loss of FMRP in brain cells, in hopes of identifying pathways to target for potential therapeutics.

Cells respond to signals (e.g. electrical, chemical signals) by signaling cascades that relay information from the outside of the cell to the nucleus where changes in genes occur. We want to test how the loss of FMRP affects a neural cell’s signal transduction cascades. One signal transduction relay molecule that has been implicated in Fragile X is cyclic AMP (cAMP). Previous work by Fragile X researcher Elizabeth Berry-Kravis and colleagues showed that cAMP is lower in blood cells from Fragile X individuals. We have found that cells of the nervous system are also not able to produce cAMP as well in Fragile X. Lowered cAMP signal transduction affects how FX cells in the brain respond to stimuli and how they function during development.

In this project, we want to understand why cAMP production is lower in Fragile X. How does the lack of FMRP cause lower cAMP signaling? Finally, using a drug assay on human FX cells, we hope to find compounds that can rescue the cAMP defect in Fragile X cells.

The team published their findings:  The Cyclic AMP Cascade Is Altered in the Fragile X Nervous System, by Daniel J. Kelley, Richard J. Davidson, Jamie L. Elliott, Garet P. Lahvis, Jerry C. P. Yin, and Anita Bhattacharyya.

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.